Clinical Trials Browser

Phase 2 × Esthesioneuroblastoma, Olfactory × apatinib × Clear all

NCT06308575 2025-01-10

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Phase 2 Withdrawn

Esthesioneuroblastoma, Olfactory